WST · West Pharmaceutical Services Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Operating Profit non-GAAP | $197.4M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Reported Operating Profit $179.1M
+$18.3M Unallocated items
= Adjusted Operating Profit $197.4M
|
|||
| Adjusted Operating Profit Margin non-GAAP | 22.6% | Q2 26 | — |
| Adjusted-diluted EPS non-GAAP | $4.5 | Six Months ended June 30, 2026 | — |
|
|
|||
| Capital expenditures | $85.9M | H1 26 | — |
|
|
|||
| Free cash flow non-GAAP | 128M | H1 2026 | — |
|
|
|||
| HVP Components net sales | $424.1M | Q2 2026 | — |
| HVP Delivery Devices net sales | $131.2M | Q2 2026 | — |
|
|
|||
| Operating cash flow | $213.9M | H1 26 | — |
|
|
|||
| Organic net sales growth non-GAAP | 12.7% | Q2 2026 | — |
|
|
|||
| Organic Net Sales Growth Rate (Decline) (Non-U.S. GAAP) non-GAAP | 13.9% | Six Months Ended June 30, 2026 | — |
| Proprietary Products gross profit margin | 42.6% | Q2 26 | — |
| Proprietary Products OP margin | 29.3% | Q2 26 | — |
| Proprietary Products Segment net sales | $722.6M | Q2 26 | +16.6% |
|
|
|||
| Shares repurchased | 1.8M | Six Months Ended June 30, 2026 | — |
| Standard Products net sales | $167.3M | Q2 2026 | — |
|
|
|||
| West Vantage gross profit margin | 14.2% | Q2 26 | — |
| West Vantage OP margin | 8.6% | Q2 26 | — |
| West Vantage Segment net sales | $149.7M | Q2 2026 | +2.0% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WST
this stock
West Pharmaceutical Services Inc
|
$24.39B | +26.0% | +2.0% | 44.4 | 3.6% |
|
ISRG
Intuitive Surgical Inc
|
$137.90B | -30.9% | +20.5% | 44.8 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.24B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$45.86B | -18.8% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.55B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WST | -1.4% | -3.5% | +39.8% | +1.7% | +26.0% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -1.0% | -6.1% | +29.1% | -1.1% | +13.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.